Primary ovarian leiomyosarcoma in a woman in her 70s: A case report Authors: Vishal Bahall, Lance De Barry Published: 2026 ABSTRACT AbstractPrimary ovarian leiomyosarcoma is a rare clinical entity within the spectrum of gynecologic sarcomas. Accounting for less than 0.1% of all ovarian malignancies, ovarian leiomyosarcomas are highly aggressive mesenchymal tumours that arise from smooth muscle.This report describes the case of a 78-year-old postmenopausal woman who presented with non-specific lower abdominal discomfort, bloating and immobile palpable pelvic mass. Cross-sectional computed tomography demonstrated a large heterogenous adnexal mass with indeterminate features arising from the right ovary. The patient underwent primary cytoreductive surgery, including a total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings and infracolic omentectomy. Histopathology confirmed a stage IA right ovarian sarcoma favouring leiomyosarcoma morphology, with no evidence of uterine involvement or other primary source.Primary ovarian leiomyosarcomas tend to masquerade as epithelial neoplasms preoperatively. The aggressive clinical course, resistance to conventional chemotherapy and absence of established treatment protocols underscore the diagnostic challenges posed by primary ovarian leiomyosarcomas. This case highlights the importance of considering mesenchymal tumours in the differential diagnosis of atypical adnexal masses and underscores the need for formalized therapeutic guidelines for this rare tumour subtype.Keywords: Ovarian leiomyosarcoma, Ovarian cancer, Tumour markers, Adjuvant therapy, Immunohistochemistry, Radical surgery Introduction Primary ovarian leiomyosarcoma (POLMS) is an exceedingly rare and aggressive mesenchymal neoplasm [1]. Compared with its uterine counterpart, the ovary is an unusual site for smooth muscle tumorigenesis, as it lacks native benign smooth muscle tissue [2]. It is postulated that POLMS arises from the smooth muscle cells of the ovarian vasculature or from Mullerian stromal elements undergoing mesenchymal differentiation [2]. The rarity of this tumour, in addition to its non-specific clinical and radiological profile, contributes to frequent diagnostic delays and under-recognition. The clinical presentation of POLMS is often insidious. It typically affects postmenopausal women, although occurrences in younger patients have been recorded [3]. Patients may report nonspecific symptoms, such as abdominal distension, pelvic pressure, or dull abdominal discomfort [4]. Serum tumour markers such as CA-125 are typically within normal limits or only marginally elevated, offering little diagnostic guidance [5]. The definitive diagnosis of POLMS is based on immunohistopathological assessment [6]. Immunohistochemistry often demonstrates strong expression of desmin, smooth muscle actin and caldesmon, and also helps to exclude high-grade endometrial stromal sarcomas or sarcomatoid carcinomas [6]. Currently, there are no standardized treatment protocols for POLMS. However, a comprehensive approach to treatment that involves surgical staging, systemic chemotherapy and selective use of radiotherapy may improve patient outcomes [1]. While surgical resection remains the cornerstone of initial management, leiomyosarcomas are notoriously refractory to both chemotherapy and radiotherapy, resulting in limited responsiveness and poor long-term survival [3]. Moreover, POLMS carries a high risk of both local recurrence and hematogenous spread [7]. This case report highlights a rare diagnosis of POLMS confirmed following cytoreductive surgery for a presumed epithelial ovarian malignancy in a postmenopausal woman. The final histopathological analysis revealed a high-grade smooth muscle tumour confined to the ovary, with no evidence of uterine or extra-ovarian origin. To the authors' knowledge, this represents one of the first documented cases of primary ovarian leiomyosarcoma in the Caribbean, underscoring both the diagnostic challenges and therapeutic uncertainties associated with this rare and aggressive neoplasm. Case Presentation A 78-year-old woman, para 1 + 0, presented to the gynaecology clinic with a six-month history of progressively worsening lower abdominal pain. She denied associated symptoms such as bloating, weight loss, altered bowel habits or constitutional symptoms. Her gynecologic history was unremarkable, with no prior surgeries or known pelvic pathology. The patient's medical history included type II diabetes mellitus, chronic hypertension and a transient ischemic attack with hemorrhagic conversion one year prior. She was fully ambulatory, cognitively intact, and maintained independent function at baseline. On physical examination, the abdomen was soft but distended, with a firm, non-tender pelvic mass palpable up to the umbilicus. A bimanual examination confirmed a large, fixed, right adnexal mass with limited mobility. There was no associated vaginal discharge or abnormal bleeding, and the cervix appeared atrophic but grossly normal on speculum examination. Baseline laboratory investigations, including a full blood count and renal and liver function tests, were within normal limits. Tumour markers were also within normal parameters: CA-125 measured 12.21 U/ml, CA-19-9 was 6.64 U/ml, and carcinoembryonic antigen (CEA) was 0.76 ng/ml. A contrast-enhanced computed tomography (CT) scan of the abdomen and pelvis demonstrated a well-defined, complex right adnexal mass measuring approximately 10 cm with both solid and cystic components (Fig. 1). There was no radiological evidence of ascites, peritoneal nodularity, or lymphadenopathy. The uterus appeared small and atrophic, with no apparent involvement. Computed tomography image of the pelvis demonstrating a well-defined right adnexal mass (white arrow) with both solid and cystic components. Following a preoperative risk assessment, the patient underwent an uncomplicated total abdominal hysterectomy, bilateral salpingo-oophorectomy, and infracolic omentectomy. Intraoperatively, the tumour was identified as a well-circumscribed mass arising from within the right ovarian parenchyma with an intact ovarian capsule and no continuity with the broad ligament, uterine serosa, or adnexal supporting structure. The ovarian mass was 10 cm in diameter, with smooth external contours, cystic degeneration and firm, solid areas (Fig. 2). The mass was removed intact, without capsular breech or spillage. The uterus was approximately 6 weeks in size. The omentum appeared grossly normal, and no peritoneal disease was visualized. Right ovarian mass measuring 10 cm × 10 cm with cystic degeneration and solid areas. Histopathological examination of the right ovarian mass demonstrated a malignant spindle cell neoplasm arranged in intersecting fascicles and composed of pleomorphic cells with elongated hyperchromatic nuclei and eosinophilic cytoplasm (Fig. 3). Marked diffuse cytologic atypia was present, with occasional bizarre tumour giant cells. Numerous mitotic figures, including atypical forms, were readily identified, supporting a high mitotic index. Foci of tumour cell necrosis were also identified, with features consistent with coagulative tumour cell necrosis. Immunohistochemically, caldesmon showed strong diffuse positivity, while desmin was weakly positive. The Ki-67 proliferative index was markedly elevated (70–80%). Taken together, the morphologic and immunophenotypic findings supported a diagnosis of leiomyosarcoma confined to the ovary. The contralateral adnexa, uterus, cervix and omentum were uninvolved. Based on current findings, the provisional FIGO stage was 1A. Histologic section of the right ovarian mass demonstrating pleomorphic spindle cells (white arrow) with elongated nuclei and occasional bizarre cells (red arrow). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) The patient was referred to the medical oncology service for further evaluation and consideration of adjuvant therapy. Her case was discussed at the multidisciplinary team meeting. She subsequently declined adjuvant treatment and opted for close oncologic surveillance. A structured surveillance plan was established following a multidisciplinary discussion. The patient was reviewed at 6-week intervals following the immediate postoperative period, with clinical assessments focused on symptomatology, abdominal examination, and overall clinical status. Serial tumour markers were not utilized given their limited utility in leiomyosarcoma; instead, surveillance relied primarily on clinical evaluation and imaging. A baseline postoperative CT scan of the chest, abdomen, and pelvis performed at three months demonstrated no evidence of residual or recurrent disease. Thereafter, interval imaging was scheduled at 6-monthly intervals for the first two years, given the early recurrence pattern associated with leiomyosarcomas. At the time of last follow-up, the patient remained asymptomatic with no radiological evidence of disease recurrence. She continued to be followed up under joint gynaecologic oncology and medical oncology care. Discussion Primary ovarian leiomyosarcoma is an extraordinarily rare malignancy, constituting less than 0.1% of all ovarian tumours [1]. Fewer than 80 cases have been reported in the literature to date and, as such, its natural history remains incompletely defined. Most documented cases occur in women between the ages of 45 and 60, with a peak incidence in the postmenopausal period [3]. Unlike epithelial ovarian carcinoma, which shows a clear age association with perimenopausal transition and increased parity, the demographic distribution of POLMS lacks a well-established pattern due to the rarity of the disease [3]. Although definitive risk factors for POLMS have not been conclusively identified, several hypotheses have been proposed. These include obesity, diabetes, unopposed estrogen exposure, which has been implicated in mesenchymal tumour development in other gynecologic sites, prior pelvic irradiation, and tamoxifen use [8]. Alterations in tumour suppressor genes such as TP53 and RB1 have been associated with soft tissue sarcomas and may be relevant in a subset of patients with POLMS, although genetic profiling data remain sparse [8]. The pathogenesis of POLMS remains unelucidated, primarily because the ovary lacks a prominent population of smooth muscle cells [4]. The tumour is believed to arise from the smooth muscle walls of ovarian blood vessels, subcoelomic mesenchyme or from myoid stromal components of the ovarian ligament [2]. Furthermore, it is postulated that malignant transformation of a pre-existing benign smooth muscle lesion, such as an ovarian leiomyoma or smooth muscle metaplasia, can give rise to POLMS, although this is rarely documented [9]. Molecularly, POLMS shares features with leiomyosarcomas in other sites, particularly the uterus [10]. Genomic alterations, including TP53 mutations, loss of heterozygosity at 10q, and overexpression of MDM2 and CDK4, have been described in leiomyosarcomas generally, though not characterized explicitly in ovarian cases [10]. The tumour's aggressive biology, high mitotic index and propensity for early hematogenous dissemination all point to a fundamentally high-grade phenotype [3]. Molecular profiling was not performed in this case due to the absence of targeted molecular assays at the institution the patient attended; however, several previously reported cases of primary ovarian leiomyosarcoma have similarly relied on histopathologic and immunohistochemical criteria without molecular confirmation. POLMS most commonly presents as a large, unilateral pelvic mass, often discovered incidentally or during evaluation for vague abdominal or pelvic symptoms [1]. Patients typically report abdominal distention, pelvic pressure, non-specific lower abdominal pain, early satiety and bloating [4]. Vaginal bleeding is less common than is the case with uterine sarcomas but may occur in patients with hormonally active tumours or coexisting endometrial pathology. Constitutional symptoms such as weight loss or fatigue are uncommon. In most cases, the tumour attains a substantial size at the time of diagnosis, often exceeding 10 cm [1]. This may reflect the tumour's indolent early growth phase followed by rapid progression once vascular invasion occurs. Unlike epithelial ovarian malignancies, leiomyosarcomas rarely present with ascites or peritoneal carcinomatosis, given their propensity for hematogenous rather than transcoelomic spread [11]. Accurate preoperative diagnosis of POLMS is exceptionally challenging. Imaging modalities such as pelvic ultrasound and computed tomography typically reveal a solid or a mixed solid-cystic adnexal mass, often with areas of necrosis or hemorrhage [12]. However, these findings are non-specific and frequently lead to misclassification as epithelial ovarian cancer or even benign fibromatous lesions. Magnetic resonance imaging (MRI) may show low T1 and heterogeneous T2 signal intensity, similar to uterine sarcomas, but its utility in differentiating mesenchymal from epithelial neoplasms remains limited [13]. Serum tumour markers, including CA-125, CA-19-9 and CEA, are generally within normal ranges or only mildly elevated, offering limited diagnostic utility [5]. Definitive diagnosis relies on postoperative histopathologic and immunohistochemical evaluation [6]. Microscopically, POLMS is characterized by fascicles of spindle cells with eosinophilic cytoplasm, marked nuclear atypia and frequent mitotic figures. Tumour necrosis and hemorrhage may also be present [6]. Immunohistochemistry (IHC) is crucial for confirming smooth muscle differentiation and excluding endometrial stromal sarcomas, undifferentiated carcinomas, or sarcomatoid variants of epithelial ovarian cancers [14]. POLMS typically exhibits diffuse positivity for desmin, smooth muscle actin (SMA), and h-caldesmon, with negative staining for cytokeratins, CD34 and S100 [15]. The immune profile supports its mesenchymal lineage and guides therapeutic considerations. Given the rarity of POLMS, diagnostic thresholds are often extrapolated from uterine smooth muscle tumour criteria. In uterine pathology, the combination of diffuse moderate to severe atypia, elevated mitotic activity, and coagulative tumour cell necrosis strongly supports leiomyosarcoma. Although these criteria have not been formally validated for ovarian smooth muscle tumours due to the scarcity of cases, they remain a practical and widely accepted framework for pathologic interpretation. In the case presented, a broader immunohistochemical panel to exclude other spindle cell neoplasms was considered. However, extended sarcoma-specific immunohistochemical markers, genetic and molecular studies were not available within the institution's pathology laboratory, and external referral for additional IHC was not feasible due to resource and logistical constraints. Despite this limitation, the diagnosis was supported by classic histomorphic features of leiomyosarcoma, including the presence of intersecting fascicles of pleomorphic spindle cells, marked nuclear atypia, and coagulative tumour necrosis. In addition, the markedly elevated Ki-67 proliferation index (70–80%) in conjunction with diffuse caldesmon positivity is a highly specific marker of smooth muscle differentiation. Radical surgery remains the primary treatment modality. Most patients undergo total abdominal hysterectomy with bilateral salpingo-oophorectomy and omentectomy [1]. The role of lymphadenectomy is controversial [5]. Although lymphatic spread is rare, comprehensive surgical staging may be performed to rule out synchronous malignancies or microscopic metastases. Complete cytoreduction with negative margins is the primary surgical goal, as residual disease is associated with poorer outcomes [1]. Adjuvant therapy is considered in most cases due to the tumour's high recurrence risk; however, its efficacy is not well documented due to the rarity of POLMS [16]. Chemotherapy protocols are typically adapted from those used in the management of uterine leiomyosarcoma and may include agents such as doxorubicin, ifosfamide, gemcitabine, or docetaxel [6]. However, leiomyosarcomas are notoriously chemoresistant, and response rates remain modest [3]. Radiotherapy is generally reserved for select cases with pelvic recurrence or close surgical margins, given the tumour's radioresistance [7]. The prognosis for patients with POLMS is guarded [7]. Despite aggressive surgical intervention, recurrence is common, typically within the first two years postoperatively [4]. Hematogenous dissemination to the lungs and bones is the predominant pattern of spread, and peritoneal involvement is rare [4]. Reported five-year survival rates are low, and as much as 80% of patients with stage II-IV disease die within a year, although data are limited by small cohort sizes and case report-based evidence [16]. According to Mandato et al., prognostic indicators include tumour size, mitotic index, degree of cytologic atypia, and completeness of resection [1]. Extra-ovarian spread at the time of diagnosis portends a poorer outcome. Ongoing surveillance, including periodic imaging and clinical evaluation, is crucial, particularly during the first 24 months after treatment [3]. Notably, tumour markers have limited value in the context of surveillance and are not routinely recommended [5]. Most authors advocate imaging at three- to six-month intervals during the first two years, followed by less frequent monitoring thereafter, although the optimal duration of follow-up remains undefined. In conclusion, primary ovarian leiomyosarcoma is an exceptionally rare and aggressive mesenchymal malignancy, often indistinguishable preoperatively from epithelial ovarian tumours due to its nonspecific clinical and radiologic features. This case reinforces the critical role of histopathology and immunohistochemistry in establishing an accurate diagnosis and highlights the limitations of current management strategies, given the tumour's resistance to conventional chemotherapy and lack of standardized treatment protocols. Complete surgical excision remains the cornerstone of care; however, the high risk of recurrence, even in early-stage disease, necessitates vigilant postoperative surveillance. This report underscores the urgent need for expanded molecular characterization and collaborative data collection to inform evidence-based guidelines and improve clinical outcomes in this rare and understudied neoplasm. Contributors Vishal Bahall contributed to patient care, conception of the case report, drafting the manuscript and revising the article critically for important intellectual content. Lance De Barry contributed to patient care, conception of the case report, drafting the manuscript, undertaking the literature review and revising the article critically for important intellectual content. Both authors approved the final submitted manuscript. Patient consent Written informed consent was obtained from the patient for the publication of this case report and accompanying images. Provenance and peer review This article was not commissioned and was peer reviewed. Vishal Bahall, an editorial board member for Case Reports in Women's Health, was not involved in editorial consideration of the manuscript and was blinded to the process. Funding No funding from an external source supported the publication of this case report. Declaration of competing interest The authors declare that they have no competing interest regarding the publication of this case report. Acknowledgements The authors would like to thank all anonymous reviewers and editors for their helpful suggestions for the improvement of this paper. References